Showing results (301-310 of 444) with videos related to
Sort By:
Pageof 45
Cancer|November 17, 2011
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic gliomaPierre Giglio, Megha Dhamne, Kenneth R Hess, et al.Frontiers in Oncology|August 19, 2022
Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2Mythili Merchant, Margarita Raygada, Ying Pang, et al.Journal of Neuro-Oncology|July 14, 2016
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastomaShiao-Pei Weathers, Xiaosi Han, Diane D Liu, et al.Journal of Neuro-Oncology|April 11, 2015
An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN)Mariko DeWire, Maryam Fouladi, David C Turner, et al.Neuro-Oncology|December 6, 2013
IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resectionJason Beiko, Dima Suki, Kenneth R Hess, et al.International Journal of Radiation Oncology, Biology, Physics|November 6, 2017
Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525Wenyin Shi, Molly Scannell Bryan, Mark R Gilbert, et al.Neuro-Oncology|January 3, 2018
Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordomaShuyu Hao, Hua Song, Wei Zhang, et al.Neuro-Oncology|June 13, 2017
MerTK as a therapeutic target in glioblastomaJing Wu, Lauren N Frady, Ryan E Bash, et al.Acta Neuropathologica|February 22, 2015
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomasAdriana Olar, Khalida M Wani, Kristin D Alfaro-Munoz, et al.The Lancet. Oncology|February 3, 2020
Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative reportTerri S Armstrong, Linda Dirven, David Arons, et al.Pageof 45